What is the Optimal Design-Build-Test Cycle for Clinically Relevant Synthetic CAR T Cell Therapies?

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Contributors

Yvonne Y. Chen

Wendell Lim

Megan Levings

Bruce Blazar

Giedre Krenciute

Wilson Wong

Manfred Lehner

Journal

Journal ID (nlm-journal-id): 101656080

Journal ID (pubmed-jr-id): 43733

Journal ID (nlm-ta): Cell Syst

Journal ID (iso-abbrev): Cell Syst

Title: Cell systems

ISSN (Print): 2405-4712

ISSN (Electronic): 2405-4720

Publication date Nihms-submitted: 24 January 2021

Publication date (Print): 23 September 2020

Publication date PMC-release: 04 February 2021

Volume: 11

Issue: 3

Pages: 212-214

Affiliations

University of California, Los Angeles

University of California, San Francisco

University of British Columbia; BC Children’s Hospital Research Institute

University of Minnesota

St. Jude Children’s Research Hospital

Boston University

St. Anna Children’s Cancer Research Institute

Article

Accession ID: PMC7861890 Pmcid ID: PMC7861890 Pmc-uid ID: 7861890 Manuscript ID: nihpa1663284

DOI: 10.1016/j.cels.2020.08.017

PMC ID: 7861890

PubMed ID: 32970992

SO-VID: 49ea5c08-3cb5-4b58-9439-2ee7be096284

History

Comments

Comment on this article

scite_